Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HASHEM EL-SERAG and FASIHA KANWAL.
HASHEM EL-SERAG
Connection Strength
31.703
FASIHA KANWAL
  1. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.929
  2. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.862
  3. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.840
  4. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.839
  5. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.829
  6. Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. Gastroenterology. 2021 07; 161(1):333-335.
    View in: PubMed
    Score: 0.734
  7. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.674
  8. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.650
  9. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.607
  10. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.560
  11. Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol. 2017 Aug; 112(8):1287-1297.
    View in: PubMed
    Score: 0.559
  12. The Top Five Reasons You Should Publish in Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017 02; 15(2):164-165.
    View in: PubMed
    Score: 0.539
  13. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.517
  14. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.515
  15. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
    View in: PubMed
    Score: 0.493
  16. Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci. 2015 Jul; 60(7):2030-7.
    View in: PubMed
    Score: 0.475
  17. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014 Nov; 60(5):1767-75.
    View in: PubMed
    Score: 0.460
  18. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.458
  19. Obesity and hepatocellular carcinoma: hype and reality. Hepatology. 2014 Sep; 60(3):779-81.
    View in: PubMed
    Score: 0.455
  20. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.453
  21. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1381-3.
    View in: PubMed
    Score: 0.445
  22. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):327-333.e1.
    View in: PubMed
    Score: 0.429
  23. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.427
  24. Improving quality of care in patients with cirrhosis. Clin Liver Dis (Hoboken). 2013 Jun; 2(3):123-124.
    View in: PubMed
    Score: 0.424
  25. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology. 2013 Mar; 144(3):478-81.
    View in: PubMed
    Score: 0.415
  26. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):200-3.
    View in: PubMed
    Score: 0.415
  27. a-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):441-3.
    View in: PubMed
    Score: 0.413
  28. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012 Jul; 143(1):70-7.
    View in: PubMed
    Score: 0.390
  29. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
    View in: PubMed
    Score: 0.357
  30. Hepatocellular cancer care: cost is important but only one factor of disease burden. J Hepatol. 2009 Jan; 50(1):10-2.
    View in: PubMed
    Score: 0.308
  31. A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol. BMC Health Serv Res. 2025 May 06; 25(1):645.
    View in: PubMed
    Score: 0.242
  32. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
    View in: PubMed
    Score: 0.238
  33. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.233
  34. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.227
  35. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.226
  36. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.225
  37. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024 Feb 16.
    View in: PubMed
    Score: 0.222
  38. The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Pancreas. 2024 Jan 01; 53(1):e27-e33.
    View in: PubMed
    Score: 0.218
  39. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Dig Dis Sci. 2023 09; 68(9):3634-3643.
    View in: PubMed
    Score: 0.213
  40. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.208
  41. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.204
  42. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.200
  43. The Texas collaborative center for hepatocellular cancer: Reducing liver cancer mortality in Texas through coordination, collaboration and advocacy. Front Oncol. 2022; 12:953933.
    View in: PubMed
    Score: 0.200
  44. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.199
  45. Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes. Dig Dis Sci. 2023 01; 68(1):312-322.
    View in: PubMed
    Score: 0.198
  46. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.198
  47. Reply. Hepatology. 2022 Aug; 76(2):E50.
    View in: PubMed
    Score: 0.195
  48. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.194
  49. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
    View in: PubMed
    Score: 0.193
  50. Why Do Small Intraductal Papillary Mucinous Neoplasms Create Such a Huge Management Challenge?: How International Classification of Diseases Codes Have Failed Us. Pancreas. 2022 02 01; 51(2):e13-e15.
    View in: PubMed
    Score: 0.193
  51. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.192
  52. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.191
  53. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.188
  54. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 11; 161(5):1657-1669.
    View in: PubMed
    Score: 0.188
  55. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.186
  56. Correction to: Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 Aug; 66(8):2842.
    View in: PubMed
    Score: 0.186
  57. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.186
  58. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.186
  59. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.186
  60. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.177
  61. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.176
  62. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.
    View in: PubMed
    Score: 0.174
  63. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
    View in: PubMed
    Score: 0.174
  64. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
    View in: PubMed
    Score: 0.172
  65. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.171
  66. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.170
  67. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.170
  68. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
    View in: PubMed
    Score: 0.159
  69. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.158
  70. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. J Viral Hepat. 2019 05; 26(5):596-602.
    View in: PubMed
    Score: 0.158
  71. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.157
  72. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.156
  73. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
    View in: PubMed
    Score: 0.155
  74. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.150
  75. Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol. 2018 08; 16(8):1182-1186.e2.
    View in: PubMed
    Score: 0.149
  76. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology. 2018 07; 68(1):7-9.
    View in: PubMed
    Score: 0.149
  77. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol. 2018 07; 16(7):992-1002.e6.
    View in: PubMed
    Score: 0.147
  78. Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clin Gastroenterol Hepatol. 2018 10; 16(10):1677-1678.
    View in: PubMed
    Score: 0.146
  79. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
    View in: PubMed
    Score: 0.145
  80. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.143
  81. Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017 12; 15(12):1823-1827.
    View in: PubMed
    Score: 0.142
  82. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.142
  83. Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Dig Dis Sci. 2017 10; 62(10):2713-2718.
    View in: PubMed
    Score: 0.142
  84. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.141
  85. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.137
  86. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.135
  87. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.134
  88. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.133
  89. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.133
  90. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Dig Dis Sci. 2017 01; 62(1):76-83.
    View in: PubMed
    Score: 0.133
  91. Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clin Gastroenterol Hepatol. 2016 12; 14(12):1678-1680.
    View in: PubMed
    Score: 0.132
  92. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol. 2017 02; 15(2):273-281.e1.
    View in: PubMed
    Score: 0.132
  93. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.132
  94. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis. 2016 08 01; 63(3):291-9.
    View in: PubMed
    Score: 0.129
  95. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.129
  96. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
    View in: PubMed
    Score: 0.127
  97. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Dig Dis Sci. 2016 06; 61(6):1714-20.
    View in: PubMed
    Score: 0.126
  98. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.125
  99. The Art and Science of Managing Liver Disease. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2029-30.
    View in: PubMed
    Score: 0.123
  100. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver?Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):191-202.e1-4; quiz e20.
    View in: PubMed
    Score: 0.123
  101. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1521-31.e3.
    View in: PubMed
    Score: 0.120
  102. Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin Gastroenterol Hepatol. 2015 Apr; 13(4):805-7.
    View in: PubMed
    Score: 0.118
  103. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.117
  104. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
    View in: PubMed
    Score: 0.115
  105. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.114
  106. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015 Jan; 110(1):10-4.
    View in: PubMed
    Score: 0.113
  107. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.111
  108. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.107
  109. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther. 2013 Jul; 38(1):28-37.
    View in: PubMed
    Score: 0.106
  110. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.104
  111. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1342-1359.e2.
    View in: PubMed
    Score: 0.101
  112. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.100
  113. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.099
  114. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
    View in: PubMed
    Score: 0.093
  115. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.090
  116. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology. 2011 Jan; 53(1):42-52.
    View in: PubMed
    Score: 0.089
  117. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.088
  118. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):709-17.
    View in: PubMed
    Score: 0.085
  119. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1078-87.
    View in: PubMed
    Score: 0.076
  120. Racial and ethnic disparities in extended criteria allograft use for liver transplantation. Liver Transpl. 2025 Jun 01; 31(6):844-847.
    View in: PubMed
    Score: 0.059
  121. Temporal Changes in Risk Factors of Hepatocellular Carcinoma in a Prospective Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2025 Jun; 23(7):1268-1270.e2.
    View in: PubMed
    Score: 0.059
  122. Prevalence and Outcomes of Emergency Presentations of Colorectal Cancer in Veterans Affairs Health Care System. Dig Dis Sci. 2025 Jan; 70(1):177-190.
    View in: PubMed
    Score: 0.059
  123. Shared genetic architecture of non-viral cirrhosis with several pleiotropic traits: A nested case-control study in the UK Biobank. Liver Int Commun. 2024 Dec; 5(4).
    View in: PubMed
    Score: 0.058
  124. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.058
  125. Defining and Understanding Diagnostic Delays Among Pancreatic Cancer Patients: A Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2025 Jan; 23(1):179-181.e3.
    View in: PubMed
    Score: 0.057
  126. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.055
  127. The Association between Caffeine Intake and the Colonic Mucosa-Associated Gut Microbiota in Humans-A Preliminary Investigation. Nutrients. 2023 Apr 03; 15(7).
    View in: PubMed
    Score: 0.052
  128. The Predictive Performance of Contemporary Guideline Recommendations for Helicobacter pylori Testing in a United States Population. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1771-1780.
    View in: PubMed
    Score: 0.051
  129. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.050
  130. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.050
  131. Dietary Fatty Acid Intake and the Colonic Gut Microbiota in Humans. Nutrients. 2022 Jun 29; 14(13).
    View in: PubMed
    Score: 0.050
  132. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.049
  133. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299.
    View in: PubMed
    Score: 0.048
  134. Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microb Ecol. 2022 Apr; 83(3):811-821.
    View in: PubMed
    Score: 0.046
  135. Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. Dig Dis Sci. 2021 09; 66(9):2981-2991.
    View in: PubMed
    Score: 0.044
  136. The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. Gastroenterology. 2020 09; 159(3):1184-1185.
    View in: PubMed
    Score: 0.043
  137. Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. Infect Dis Ther. 2020 Jun; 9(2):355-365.
    View in: PubMed
    Score: 0.043
  138. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.042
  139. Dietary quality and the colonic mucosa-associated gut microbiome in humans. Am J Clin Nutr. 2019 09 01; 110(3):701-712.
    View in: PubMed
    Score: 0.041
  140. Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients. 2019 Mar 13; 11(3).
    View in: PubMed
    Score: 0.039
  141. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
    View in: PubMed
    Score: 0.039
  142. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci. 2018 05; 63(5):1173-1181.
    View in: PubMed
    Score: 0.037
  143. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.035
  144. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.034
  145. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.033
  146. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan; 14(1):124-31.e1.
    View in: PubMed
    Score: 0.031
  147. Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. Int J Mol Epidemiol Genet. 2014; 5(3):164-76.
    View in: PubMed
    Score: 0.029
  148. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
    View in: PubMed
    Score: 0.029
  149. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014 Mar; 39(5):518-31.
    View in: PubMed
    Score: 0.028
  150. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011 Mar; 53(3):737-45.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.